Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BAY1841788 (ODM-201) on Rosuvastatin PK
NCT02671097Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Primary endpoints: Area under the concentration-time curve of Rosuvastatin from time zero to 24 hours and Maximum drug concentration in plasma of Rosuvastatin at 24 hours. Started Feb 2016; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02671097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671097.